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Low-count monoclonal B-cell lymphocytosis is defined by the pres-ence of very low numbers of circulating clonal B cells, usually phe-notypically similar to chronic lymphocytic leukemia cells, whose
biological and clinical significance remains elusive. Herein, we re-evalu-
ated 65/91 low-count monoclonal B-cell lymphocytosis cases (54 chronic
lymphocytic leukemia-like and 11 non-chronic lymphocytic leukemia-
like) followed-up for a median of seven years, using high-sensitivity
flow cytometry and interphase fluorescence in situ hybridization.
Overall, the clone size significantly increased in 69% of low-count mon-
oclonal B-cell lymphocytosis cases, but only one subject progressed to
high-count monoclonal B-cell lymphocytosis. In parallel, the frequency
of cytogenetic alterations increased over time (32% vs. 61% of cases,
respectively). The absolute number of the major T-cell and natural killer
cell populations also increased, but only among chronic lymphocytic
leukemia-like cases with increased clone size vs. age- and sex-matched
controls. Although progression to chronic lymphocytic leukemia was
not observed, the overall survival of low-count monoclonal B-cell lym-
phocytosis individuals was significantly reduced vs. non-monoclonal B-
cell lymphocytosis controls (P=0.03) plus the general population from
the same region (P≤0.001), particularly among females (P=0.01); infec-
tion and cancer were the main causes of death in low-count monoclonal
B-cell lymphocytosis. In summary, despite the fact that mid-term pro-
gression from low-count monoclonal B-cell lymphocytosis to high-count
monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
appears to be unlikely, these clones persist at increased numbers, usually
carrying more genetic alterations, and might thus be a marker of an
impaired immune system indirectly associated with a poorer outcome,
particularly among females.
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in
the Western world, typically affecting older patients, particularly males, with a
median age at diagnosis of 70 years (y) old.1 It is characterized by the accumulation
of mature B cells in peripheral blood (PB), bone marrow (BM) and also secondary
lymphoid tissues, with a uniquely aberrant CD19+ CD20+lo CD5+/++ CD23+ sIgM-/+lo
phenotype and restricted immunoglobulin (Ig) light chain usage.2,3 Typically, CLL
shows a heterogeneous clinical outcome; thus, whereas in
some patients the disease remains stable and they will
never require treatment, in around 70% of cases treatment
is required and results in variable outcomes, from com-
plete response and prolonged survival to refractory disease
and death.3–5
Currently, it is well established that virtually every CLL
case is preceded by monoclonal B-cell lymphocytosis
(MBL) defined by smaller numbers of circulating PB clonal
CLL-like B-cells (<5,000 clonal B-cells/mL) in the absence
of any clinical symptoms or signs of disease.6 In 2010,
MBL was further subdivided into low-count (MBLlo) and
high-count MBL (MBLhi), depending on the number of PB
clonal B cells (lower vs. higher than 0.5x109/L, respective-
ly).7 While MBLhi has been reported to progress to overt
CLL requiring treatment at a rate of 1–2% cases per year,8,9
no information is available at present regarding the ≥5-
year risk of progression of MBLlo to MBLhi and CLL.10
The detection of MBLlo has become routinely feasible
due to the use of highly sensitive flow cytometry (FCM)
approaches for the screening of subjects from the general
population who present normal blood cell counts. Of
note, the prevalence of MBLlo is significantly higher than
that of MBLhi and CLL, with a frequency that ranges
between 3% and 14% of the general adult (≥40y) popula-
tion, depending on the sensitivity of the FCM technique
used.11 Independently of the method, it is well-established
that the incidence of MBLlo progressively increases with
age, with a prevalence >20% among individuals of more
than 70 years of age.12 Whether MBLlo represents the nor-
mal counterpart of CLL (e.g., some studies suggest that
MBLlo clones are more likely related to immunosenes-
cence)13 or a very early stage of development of CLL,
remains an open question. This is partially because, in
contrast to MBLhi, long-term follow-up studies in large
series of MBLlo cases have not been reported thus far,
which limits our understanding of the biological and clin-
ical significance of very low numbers of circulating CLL-
like clones, as well as those factors and mechanisms
involved in potential long-term progression of (conceiv-
ably) a minor proportion of all MBLlo cases to MBLhi and
CLL; likewise, little information is available about the evo-
lution of non CLL-like MBL. Such information is critical to
a better understanding of the ontogenesis of CLL from the
very early stages of the disease, and to better identify MBL
patients with stable vs. progressive B-cell lymphocytosis
who might benefit from a closer clinical follow-up.
Herein, we report on a cohort of 91 MBLlo (CLL-like and
non CLL-like) subjects identified in a population-based
screening study and followed for a minimum of five years
(median >seven years). Our primary goal was to deter-
mine the rate of medium-term progression of MBLlo to
MBLhi and CLL, and to identify the most relevant clinical




The baseline study was conducted from December 2007 to
October 2009, when PB samples from 639 healthy adult (≥40y)
volunteers (54% females/46% males) from the general population
of the same geographical area (Salamanca, Northwest of Spain)
were screened for the presence of small B-cell clones, using highly
sensitive FCM.12,14 At inclusion, all subjects had normal PB cell
counts and did not suffer from any hematological/immunological
disease, as described elsewhere.1,6 In 91/639 subjects studied
(14.2%), ≥1 PB clonal B-cell population was detected at recruit-
ment; in the vast majority of them (80/91; 88%) clonal B cells were
consistent with CLL-like MBLlo (<0.5x109clonal B cells/L showing
a CLL-like phenotype), whereas the remaining 11 individuals
(12%) were classified as non CLL-like MBLlo.12,14 MBLlo subjects
were re-evaluated at a median time of seven years after recruit-
ment (range: 61 to 95 months). All subjects gave their written
informed consent at baseline for both the initial and the follow-up
studies, and they filled out an epidemiological questionnaire with
demographic and (self-reported) medical information, under the
supervision of his/her primary care doctor.15 The study was
approved by the Ethics Committee of the University Hospital of
Salamanca (Spain).
Flow cytometry immunophenotypic studies
Overall, 1-4 mL of ethylenediamine tetraacetic acid (EDTA)-
anticoagulated PB was collected per case and follow-up time-
point; subsequently it was processed and analyzed using previous-
ly reported highly sensitive FCM approaches12,14,16,17 (Online
Supplementary Methods and Online Supplementary Table S1). 
Interphase fluorescence in situ hybridization (iFISH)
studies studies
The most common CLL - i.e., del(13q14), trisomy 12,
del(11q)(ATM) and del(17p)(TP53) - along with other B-cell chronic
lymphoproliferative disorders (B-CLPD)-associated cytogenetic
alterations were investigated by iFISH on fluorescence-activated
cell sorting (FACS)-purified (sorted) single clonal B cells (≥95%
purity), as previously described18 (Online Supplementary Table S2).
A total of 31/91 PB samples studied at baseline and 56/65 at fol-
low-up (year +7) were analyzed by iFISH; in 21 cases (18 CLL-like
and three non CLL-like MBLlo) paired samples were analyzed by
iFISH at both baseline and year +7. The potential presence of
del(13q14) was also tested in non-clonal B-cells from 5/7 MBLlo
cases found to have del(13q14)+ MBL cells. 
Statistical analyses
All conventional statistical analyses (i.e., descriptive statistics,
univariate analyses, including overall survival (OS) analysis, as
well as multivariate analyses to predict the variables independent-
ly associated with a greater/lower risk of death), were performed
with SPSS 19.0 software (SPSS-IBM, Armonk, NY, USA), using the
tests, databases and statistical significance values detailed in
Online Supplementary Methods. Appropriate tests were further used
to objectively evaluate real changes in the size of the B-cell clones
studied during follow-up (resampling bootstrap method)19 and to
build a predictive linear regression model to estimate the time
CLL-like MBLlo clones might potentially take to progress to MBLhi
and CLL, using MATLAB R2015a (Mathworks, Natick, MA, USA)
(Online Supplementary Methods).
Results
Follow-up of the MBLlo cohort
From those 91 MBLlo individuals identified in the screen-
ing study performed in the general population of
Salamanca between 2007 and 2009,12,14 65 -71% of MBLlo
cases from the original series; 29 males and 36 females;
median age at baseline 70 (range: 43-84 years old)-; were
re-evaluated after a median follow-up of seven years
(range: 61 to 95 months) (Table 1). These 65 individuals
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were representative of the original MBLlo cohort for all
variables analyzed, except for a significantly lower age
(P=0.02) vs. those 26 individuals that could not be fol-
lowed - median age of 75 (range: 48-95 years)-. These later
subjects could only be re-evaluated for their death vs. alive
status at the end of the study because of: i) 12/26 (46%)
died before the fifth year of follow-up; ii) 2 subjects
declined continuing their participation in the study; and
iii) the remaining 12 cases were lost to follow-up after >5y
from recruitment. Eight of 65 cases followed for >5y
(12%) died afterward, making a total of 21 (26%) deaths
among MBLlo cases included in OS analyses.
In all 65 individuals who were evaluated after five years,
≥1 clonal B-cell population was reliably identified in PB at
follow-up. In 22/65 (34%) cases ≥2 clones were detected
(vs. 32% at baseline), resulting in a total of 86 MBLlo clones
detected (Table 1 and Table 2). All MBLlo clones showed an
identical phenotype at both time-points (Table 2). Thus,
74/86 B-cell clones (86%) showed a classical CLL-like phe-
notype and 12 (14%) were classified as non CLL-like MBL
clones. At year +7, 35/74 CLL-like clones (47%) corre-
sponded to monoclonal cases and the remaining 39 (53%),
to 19 subjects with bi(multi)clonal CLL-like MBLlo (Table
2); in two subjects, CLL-like and non CLL-like clones
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Table 1. Clinical and biological characteristics of MBLlo subjects at baseline and after follow-up (year +7).
All subjects (n=65) CLL-like MBLlo subjects Non CLL-like MBL subjects P
(n=54) (n=11)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
Follow-up time (months) 0 84 0 84 0 83 NA
(61-95) (61-95) (63-87)
Male/Female* 29/36 22/32 7/4 NA
(45%/55%) (41%/59%) (64%/36%)
Age, years 70 75 68 75 76 83 <0.01a,b,c
(43-84) (49-91) (43-84) (49-91) (58-81) (65-88)
Leukocytosis (>10x109/L)* 0 2 0 2 0 0 NS
(0%) (3%) (0%) (3%) (0%) (0%)
Lymphocytosis (>4x109/L)* 0 3 0 2 0 1 NS
(0%) (5%) (0%) (4%) (0%) (9%)
N. total T cells/mL 1261 1448 1290 1508 1111 1206 <0.01a,b
(341-2428) (276-3753) (341-2428) (460-3753) (796-1965) (276-2907)
N. CD4+ T cells/mL 687 840 684 898 732 629 0.015a,b
(253-1572) (184-2045) (253-1572) (227-2045) (351-1395) (184-1995)
N. CD8+ T cells/mL 449 491 446 479 453 617 <0.03a,b
(71-1154) (66-1742) (71-1154) (96-1742) (237-750) (66-848)
N. CD4+/CD8+ T cells/mL 4.3 8.2 4.5 8.2 4.3 8.2 <0.02a,b,c
(0.19-38) (1.1-147) (0.55-37) (1.3-147) (0.19-27) (1.1-29)
N. CD4–/CD8– T cells/mL 56 62 58 64 36 34 <0.05a,b
(8.1-254) (1.9-407) (8.0-214) (1.9-338) (11-254) (8.1-406)
N. NK cells/mL 304 373 297 373 394 372 0.001a,b
(76-1138) (87-3415) (76-1138) (89-3415) (150-848) (178-937)
N. total B cells/mL 133 155 132 150 137 190 <0.01a,b
(26-1173) (22-1218) (41-478) (28-1218) (26-1173) (22-1207)
N. normal B cells/mL 119 116 126 140 72 45 0.08b
(23-478) (21-536) (37-478) (26-536) (23-136) (21-190)
N. clonal B cells/ mL 0.99 2.0 0.75 1.7 56 90 <0.001a,b
(0.03-1101) (0.05-1149) (0.03-66) (0.05-808) (0.62-1101) (1.3-1149)
Subjects with ≥2 MBL clones* 21 22 18 19 3 3 NS
(32%) (34%) (33%) (35%) (27%) (27%)
Progression * NA 1 NA 1 NA 0 NA
(to MBLhi) (2%) (2%) (0%)
Deaths* NA 8 NA 7 NA 1 NA
(12%) (13%) (9%)
CLL-like or non CLL-like with ≥1 B-cell clone with different phenotypes were classified depending on the phenotype of the larger clone. Results expressed as median (range)
or *as number of cases (percentage). aBaseline vs. follow-up (year +7) for all cases. bBaseline vs. follow-up (year +7) for CLL-like MBL cases. cBaseline vs. follow-up (year +7)
for non CLL-like MBL cases. CLL: chronic lymphocytic leukemia; MBLhi: high-count monoclonal B-cell lymphocytosis; MBLlo: low-count monoclonal B-cell lymphocytosis; N: num-
ber; NA: not applicable; NK: natural killer; NS: not statistically significantly different (P>0.05).
coexisted. Of note, two individuals carrying two CLL-like
B-cell clones became “monoclonal” while a second clone
emerged in one monoclonal CLL-like MBLlo case at seven
years follow-up. In turn, non CLL-like clones (n=12)
showed phenotypic profiles identical to those observed at
baseline and comparable to those of different B-CLPD, as
detailed in Online Supplementary Table S3.6
Clonal B-cell load in PB at re-evaluation (year +7).
Overall, a significant (P≤0.001) increase in the median
size of MBLlo clones was found at follow-up, both for
CLL-like (≈2-fold median increase) and for non CLL-like
MBLlo clones (≈3-fold median increase) (Table 2 and Figure
1A,B). Such increased absolute number of clonal B-cells
over time was associated with a significantly increased
(P≤0.001) percentage of clonal B cells from all PB B cells
(Table 2). In detail, most MBLlo clones (59/86; 69%)
showed significantly increased numbers at re-evaluation
vs. baseline, while the remaining 27 B-cell clones persisted
at similar (16%) or lower levels (15%); this behavior was
very similar for CLL-like and non CLL-like clones (Table
2). Of note, 30/35 (86%) CLL-like clones from
(mono)clonal cases increased in size at follow-up vs. only
21/39 (54%) clones from bi(multi)clonal cases (P=0.004).
Interestingly, among non CLL-like clones, most marginal
zone lymphoma-like clones increased (5/6; 83%), while
the two mantle cell lymphoma-like B-cell clones
decreased significantly in number (Online Supplementary
Table S3). 
Cytogenetic alterations of MBLlo clonal B cells at 
baseline and follow-up
The overall frequency of CLL-like MBLlo cases carrying
CLL-associated cytogenetic alterations, for example
del(13q14), trisomy 12, del(11q)(ATM) and del(17p)(TP53),
at baseline was of 29% (7/24 cases tested). At recruitment
del(13q14)(D13S25) was found in 56%±34% cells from
6/20 cases evaluated (30%), the RB1 gene was additionally
involved in 3 of them, and trisomy 12 was present in the
remaining case (59% of cells), both as single alterations.
After seven years of follow-up, the percentage of cytoge-
netic altered cases augmented to 62% of MBLlo cases
(31/50 cases, including 15 cases studied at baseline).
Interestingly, all cytogenetic alterations observed at base-
line also remained at follow-up; in addition, 4/15 (27%)
individuals studied at both time-points further acquired
del(13q14)(D13S25) (Online Supplementary Table S4).
Overall, del(13q14)(D13S25) remained the most frequent
alteration at follow-up (27/48; 56%), affecting 32±27% of
CLL-like cells. Of note, in five cases in which clonal B cells
showed del(13q14)(D13S25), non-clonal B cells were also
studied for this alteration, and  was found to be absent in
all of them. RB1 gene involvement was identified in only
1/7 cases tested; furthermore, trisomy 12 was restricted to
one patient who had the same abnormality at baseline
(Table 3). Clonal B cells from one individual in whom
del(17p)(TP53) was not investigated at baseline was found
to carry this cytogenetic alteration in 10% of cells at fol-
low-up. Alterations involving 14q32 were investigated
only at follow-up in a subset of 20 CLL-like MBLlo cases,
being found in five (20%) patients (Table 3).
Regarding non CLL-like clones, t(11;14)(q13-q32) was
detected in 100% of clonal B cells from one of the two
MCL-like cases studied, while del(7q32) was detected in
2/5 splenic marginal zone lymphoma (SMZL)-like cases
(Table 3). None of the cases investigated showed t(14;18)
(data not shown).
Distribution of normal residual T-, B- and NK-cell 
populations
The PB counts of total T cells and their CD4+CD8–,
CD8+CD4– and CD4–CD8-/lo subsets, as well as NK cells
and normal residual polyclonal B cells was significantly
increased (P<0.05) in CLL-like MBLlo at follow-up vs. base-
line (Table 1). In contrast, among non CLL-like MBL cases,
CD4+CD8+ T cells were the only lymphoid subset signifi-
cantly increased (P=0.02)  at the seven year follow-up. To
rule out a potential age-related bias and further confirm
these findings, we compared the number of PB normal
lymphocyte subsets at seven years follow-up vs. a large
series of non-MBL healthy donors matched per age and
sex distribution to the CLL-like MBLlo cases at seven years
(Online Supplementary Table S5) and the same differences
were found, ruling out an impact of sex or more advanced
age on the increased PB residual lymphocyte counts. No
significant correlation (P>0.05) was revealed between the
absolute number of clonal B cells and any of the normal
residual PB lymphocyte subsets analyzed (data not shown).
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Table 2. Biological characteristics of MBLlo clones at baseline and at follow-up (year +7).
All clones CLL-like MBLlo clones Non CLL-like MBL clones P
(n=86) (n=74) (n=12)
Baseline Follow-up Baseline Follow-up Baseline Follow-up
N. of clones from 44/42 42/44 36/38 35/39 8/4 7/5 NS
monoclonal/Bi(multi)clonal subjects* (51%/49%) (49%/51%) (49%/51%) (47%/53%) (67%/33%) (54%/46%)
N. of clones that increased* NA 59 NA 51 NA 8 NA
(69%) (69%) (67%)
N. clonal B cells/mL 0.06 1.3 0.46 0.85 37 68 <0.001a,b
(0.03-1101) (0.05-1146) (0.03-66) (0.05-789) (0.57-1101) (1.3-1146)
% clonal B cells 0.48% 0.95% 0.35% 0.73% 30% 60% <0.03a,b,c
(from total B cells) (0.02%-94%) (0.02%-97%) (0.02%-21%) (0.02%-65%) (0.46%-94%) (1.4%-97%)
Results expressed as median (range) or as * number of cases (percentage). aBaseline vs. follow-up (year +7) for all cases. bBaseline vs. follow-up (year +7) for CLL-like MBL
clones. cBaseline vs. follow-up (year +7) for non CLL-like MBL clones. CLL: chronic lymphocytic leukemia; MBLlo: low-count monoclonal B-cell lymphocytosis; N: number; NA: not
applicable; NS: not statistically significantly different (P>0.05).
Clinical and biological characteristics of CLL-like
MBLlo at baseline vs. follow-up, according to the kinet-
ics of the B-cell clone
Upon comparing CLL-like MBLlo cases with increased
vs. stable/decreased clonal B-cell numbers at seven years
follow-up, the former had a similar male/female distribu-
tion, but they were significantly younger (median age: 68y
vs. 78y; Table 4).
Strikingly, MBLlo cases who showed larger CLL-like
clone sizes over time also showed significantly higher
(P<0.05) numbers of the distinct normal residual T-, B- and
NK-cell subsets at follow-up (vs. baseline) (Table 4).
Moreover, in these subjects a direct correlation was
observed between the absolute number of clonal B cells
and CD4+CD8– T cells (r2=0.5; P=0.001). In contrast, no
significant (P>0.05) association was found between higher
numbers of clonal CLL-like B cells in PB over time, and an
increased frequency of cytogenetic alterations.
Interestingly, del(13q14) was the sole genetic alteration
detected at the seven year follow-up within cases with
stable/decreased CLL-like B-cell clones, while those cases
with increased CLL-like B-cell clones at year +7 showed
cytogenetic alterations other than del(13q14), e.g., trisomy
12 (1/40), del(17p)(TP53) (1/39) and t(14q32) (5/20 cases
tested) (Table 4).
Clinical outcome of MBLlo cases
Three subjects developed absolute lymphocytosis after
seven years of follow-up (median: 5.3x109 lymphocytes/L;
range: 4.1x109-5.9x109/L) in the absence of signs of dis-
ease. Two had CLL-like B-cell clones carrying del(13q14),
while the remaining case had a non CLL-like clone. In one
of the two CLL-like MBLlo cases, the size of the B-cell
clone increased over the threshold for MBLhi (>500 clonal
B cells/mL), while the other two cases remained as MBLlo.
Remarkably, these three subjects displayed the highest
increase in clone size at re-evaluation: this translated into
a significantly lower (estimated) time to progression into
CLL (median: 95y; range: 54-128y) according to the pre-
dictive mathematical model used. In turn, the estimated
time to progression to CLL for the other MBLlo individuals
was far beyond a normal life expectancy (median:
54,767y; range: 54->63 million years). 
Overall survival of MBL vs. non-MBL individuals
At the end of the study (January 2017), the clinical records
and epidemiological questionnaires from all individuals
recruited at baseline were reviewed. During follow-up,
21/89 (24%) MBLlo cases and 41/290 (14%) age- and sex-
matched non-MBLlo subjects from the original cohort had
died (P=0.03). Though the median OS for the two groups
I. Criado et al.
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Figure 1. Changes in the num-
ber of clonal B cells during fol-
low-up. Panel A shows the
absolute number of PB clonal 
B cells/mL detected in MBLlo
individuals at baseline and at
follow-up, according to the phe-
notype of the clonal population.
Panel B represents the fold-
change in the number of clonal
B cells/mL from baseline, which
is represented by the horizontal
light gray box. Notched boxes
represent 25th and 75th per-
centile values; the lines in the
middle correspond to median
values (50th percentile) and ver-
tical lines represent the highest
and lowest values that are nei-
ther outliers nor extreme values,
which are represented as single
dots. ***P-value <0.001. N:




had not been reached yet, a significantly shorter OS was
observed for MBLlo individuals vs. age- and sex-matched
non-MBL controls from the same cohort and geographical
area (10y OS rates of 76% vs. 86%, respectively; P=0.03)
(Figure 2A,B). Moreover, MBLlo subjects also showed a sig-
nificantly shortened survival vs. age-matched individuals of
the general population from the same geographical region
(8.0% vs. 1.8% in the period 2015-2016, respectively;
P<0.001) (Online Supplementary Figure S1). Interestingly,
such differences in OS were at the expense of a lower OS
of CLL-like MBLlo females, who showed a significantly
(P=0.01) higher risk of death (hazard ratio (HR) of 2.5; 95%
confidence interval (CI) of 1.2-5.4) than non-MBL females
of the same age (Figure 2C,F). Infections (21%; mostly res-
piratory infections and sepsis), cancer (36%; all solid tumors
except for an essential thrombocythemia) and cardiovascu-
lar diseases (29%; i.e., myocardial infarction and acute
ischemic stroke) were the main causes of death among
MBLlo subjects. Overall, infections were overrepresented
among the MBLlo cohort vs. age- and sex-matched subjects
from the general population of the same geographical area
(21% vs. 1.4%, respectively; P≤0.001). In contrast, the pro-
portion of deaths caused by tumors (36% vs. 26%, respec-
tively; P>0.05) and by cardiovascular diseases (29% vs.
33%, respectively; P>0.05) were similar in both groups. In
turn, no MBLlo subjects died as a cause of non-infectious res-
piratory tract diseases or genitourinary diseases, diabetes,
dementia or other nervous system disorders, which
accounted for ≈30% of deaths in the age- and sex-matched
general population cohort living in the same geographical
area. In order to identify those variables independently
associated with OS, a multivariate Cox regression analysis,
including laboratory, epidemiological and medical informa-
tion, was carried out. Advanced age-  HR of 5.1; 95% CI:
1.5-17.5; P=0.01-, co-existing cardiovascular diseases (HR:
2.7; 95%CI: 1.3-5.4; P=0.01), solid tumors (HR: 2.9; 95%CI:
1.3-6.5; P=0.007) and, to a lesser extent, the presence of
MBLlo clones (HR: 2.1, 95%CI: 0.97-4.7; P=0.06), were inde-
pendently associated with a shorter OS in the whole cohort
(Table 5 and Online Supplementary Table S6).
Discussion
Several preceding studies have shown that virtually all
CLL cases are preceded by MBLhi;8,20,21 in contrast, such a
relationship has not been demonstrated for MBLlo cases,
its role as a preleukemic condition still remaining to be
confirmed.9,21 In fact, there exist very few studies with
short-term follow-up (i.e., ≤3y) which have investigated
7y follow-up of monoclonal B-cell lymphocytosis
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Table 3. Frequency of cases with CLL-associated cytogenetic alterations and percentage of cells affected by each genetic abnormality.
All MBLlo cases CLL-like MBLlo cases Non CLL-like MBLlo cases P
Baseline Follow-up Baseline Follow-up # Baseline Follow-up
(n=31) (n=56) (n=24) (n=50) (n=7) (n=6)
N. of cases with 10/31 34/56 7/24 31/50 3/7 3/6 0.01a,b
cytogenetic alterations (%) (32%) (61%) (29%) (62%) (43%) (50%)
Chromosomal region
del(13q14)(D13S25) 7/22 (32%) 28/54 (52%) 6/20 (30%) 27/48 (56%) 1/2 (50%) 1/6 (17%) 0.06b
% altered cells 49±36% 31±27% 56±34% 32±27% 8% 7% NA
del(13q14)(RB1) 3/15 (20%) 1/7 (14%) 3/15 (20%) 1/7 (14%) NA NA NS
% altered cells 14±3% 47% 14±3% 47%
Trisomy 12 2/21 (10%) 2/55 (3.6%) 1/19 (5.3%)¥ 1/49 (2%)¥ 1/2 (50%) 1/6 (17%) NS
% altered cells 34±35% 45±35% 59% 70% 9% 20%
del(11q)(ATM) 2/12 (17%) 1/54 (1.9%) 0/10 (0%) 0/48 (0%) 2/2 (100%) 1/6 (17%) NS
% altered cells 39±44% 50% NA NA 39±44% 50%
del(17p)(TP53) 1/10 (10%) 1/54 (1.9%) 0/8 (0%) 1/48 (2.1%) 1/2 (50%) 0/6 (0%) NS
% altered cells 13% 10% NA 10% 13% NA
t(14q32)* 0/5 (0%) 7/27 (26%) NA 5/23 (22%) 0/4 (0%) 2/4 (50%) NS
% altered cells NA 33±30% 31±33% NA 38±30%
t(11;14)(q13-q32) 1/2 (50%) NA NA NA 1/2 (50%) NA NA
% altered cells 100% 100%
del(7q32) 0/1 (0%) 2/5 (40%) NA NA 0/1 (0%) 2/5 (40%) NS
% altered cells NA 20±2.1% NA 20±2.1%
3q27 (BCL6) 0/1 (0%) 0/5 (0%) NA NA 0/1 (0%) 0/5 (0%) NS
% altered cells NA NA NA NA
18q21 (MALT1) 0/2 (0%) 0/4 (0%) NA NA 0/2 (0%) 0/4 (0%) NA
% altered cells NA NA NA NA
Results expressed as number of cases (percentage of cases) and mean ± SD of percentage of cells affected by each specific genetic alteration. aBaseline vs. follow-up (year +7)
for all cases. bBaseline vs. follow-up (year +7) for CLL-like MBL cases.  cBaseline vs. follow-up (year +7) for non CLL-like MBL cases. # 2/50 individuals carried a clonal MBLlo CLL-
like population along with at least one MBLlo non CLL-like clone. ¥The same case at baseline and follow-up. *Other than t(11;14). CLL: chronic lymphocytic leukemia; MBLlo: low-
count monoclonal B-cell lymphocytosis; N: number; NA: not applicable; NS: not statistically significantly different (P>0.05).
the progression rate from MBLlo to MBLhi and CLL thus
far.10,22,23 Hence, Fazi et al. showed persistent MBLlo clones
over time in 90% of CLL-like MBLlo and only 67% of non
CLL-like clones, after a median follow-up of ≈3y.10 Herein,
we demonstrate the systematic persistence of both CLL-
like and non CLL-like MBLlo B-cell clones with an identical
phenotype to baseline after seven years follow-up in
65/65 MBLlo cases, confirming that MBLlo is not a transient
condition. Similarly, Matos et al. also found the persistence
of B-cell clones in their limited series of CLL-like MBLlo
cases (n=5) after a median follow-up of ≈7y.23 Interestingly,
in 3/56 CLL-like MBLlo cases, the number of clones identi-
fied at seven years follow-up changed, which might sug-
gest the emergence of MBLlo from an oligoclonal back-
ground that mirrors competition and natural selection
among multiple coexisting clones.24 Changes observed in
the VDJ sequences of the expanded B cells from most of
these cases (data not shown), together with the progressive-
ly decreasing rate of oligoclonality from MBLlo (12-19%)
to MBLhi (2.9-13%) and CLL (0.7-3.4%), would further
support this hypothesis.9,12,25–27 The significance of such
oligoclonal B-cell expansions in MBLlo remains unknown,
but might be the consequence of the early stages of altered
oligoclonal immune responses against multiple antigens,
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Figure 2. Overall survival from baseline (mor-
tality rates) of MBLlo individuals vs. age- and
sex-matched non-MBL controls. Left column
panels represent comparisons of overall sur-
vival curves from MBLlo subjects (black) and
age- and sex-matched non-MBL controls (dotted
gray). The same comparison is depicted for all
individuals (Panel A) and separately for males
(Panel C) and females (Panel E). In the right col-
umn, overall survival curves comparing all MBLlo
subjects with a CLL-like phenotype vs. all age-
and sex-matched non-MBL controls (Panel B).
The same subjects distributed according to sex
are shown in Panel D (males) and in Panel F
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Table 4. Clinical and biological characteristics of CLL-like MBLlo subjects at baseline and at follow-up (+7 years) according to the kinetics of the
MBL clone in PB (decreased/stable vs. increased size).
CLL-like MBLlo subjects (n=56) P
Decrease/stable B-cell clones (n=9) Increased B-cell clones (n=47)#
Male/Female* 4/5 (44%/56%) 18/29 (38%/62%) NS
Age at baseline, years 78 (55-84) 68 (43-81) 0.03
Monoclonal at follow-up* 5/9 (56%) 30/47 (64%) NS
Leukocytosis (>10x109/L) at follow-up * 0 (0%) 2 (4%) NS
Lymphocytosis (>4x109/L) at follow-up * 0 (0%) 2 (4%) NS
N. total T cells/µL
Baseline 1471 (1105-2035) 1285 (341-2428) NS
follow-up 1406 (711-2313) 1520 (460-3753) NS
P NS <0.01
N. CD4+ T cells/mL
Baseline 821 (461-1186) 448 (253-1572) NS
follow-up 792 (295-1327) 908 (227-2045) NS
P NS <0.01
N. CD8+ T cells/mL
Baseline 452 (374-900) 448 (72-1154) NS
follow-up 491 (245-1469) 467 (96-1742) NS
P NS 0.02
N. CD4+/CD8+ T cells/mL
Baseline 4.3 (0.97-17) 4.6 (0.55-37) NS
follow-up 4.7 (2.3-13) 8.6 (1.3-147) 0.03
P NS <0.001
N. CD4–/CD8– T cells/mL
Baseline 70 (8.2-214) 58 (8.0-190) NS
follow-up 60 (7.2-272) 65 (1.9-338) NS
P NS 0.02
N. total B cells/mL
Baseline 110 (41-263) 139 (50-1066) NS
follow-up 80 (29-390) 175 (28-1218) 0.02
P NS <0.01
N. normal B cells/mL
Baseline 94 (37-256) 122 (50-478) NS
follow-up 79 (26-389) 140 (27-536) NS
P NS 0.03
N. clonal B cells/mL
Baseline 0.80 (0.13-23) 0.71 (0.03-66) NS
follow-up 0.60 (0.05-3.2) 2.0 (0.10-808) 0.03
P 0.02 <0.001
% clonal B cells
Baseline 0.92 (0.10-20) 0.53 (0.02-21) NS
follow-up 0.44 (0.04-10) 1.0 (0.06-66) NS
P 0.05 <0.001
N. NK cells/mL
Baseline 304 (167-874) 292 (76-1138) NS
follow-up 492 (310-1066) 361 (87-3415) NS
P NS <0.01
Cytogenetic alterations
Baseline 0/4 (0%) 6/15 (38%) NS
follow-up 6/9 (67%) 26/41 (63%) NS
P 0.03 0.14
del(13q14)(D13S25)
Baseline 0/2 (0%) 5/13 (39%); 57±38% NS
follow-up 6/9 (67%); 17±9% 21/39 (54%); 37±29% NS
continued in the next page
in which a single clone had not yet emerged as dominant
vs. the others, as might occur at the latter, e.g., CLL stage.
Most importantly, over two thirds of all CLL-like MBLlo
clones showed a significantly increased size in PB after
seven years, while for non CLL-like clones more variable
kinetics were observed, depending on the specific pheno-
type of clonal B-cells. Interestingly, we also observed a sig-
nificant increase in the frequency of cytogenetic alter-
ations over time, evidencing that B-cell clones are not only
dynamic in terms of clone size, but also regarding their
capacity to acquire new cytogenetic alterations. Of note,
del(13q14), which has been found to be a common
mosaicism in the general population,28,29 was absent in
non-clonal B cells from 5/5 cases investigated in which
CLL-like clonal cells did carry this alteration, indicating
that the emergence of this alteration in MBLlo is specific for
the clonal population. Altogether, these findings suggest
that cytogenetic alterations are a relatively early, but not
primary, event in the natural history of MBL/CLL, and
might have a potential role in the progression of MBLlo to
MBLhi and CLL.
The presence and type of cytogenetic lesions, the IGHV
mutational status, or the presence of stereotyped recep-
tors are some of the most important prognostic factors in
CLL, which also define the outcome of MBLhi individuals;
furthermore, it might identify a subset of cases in whom
the presence of the B-cell clonal population influences
OS.30–33 Unfortunately, in the present study, the mutational
status and VDJ rearrangements were only assessed (both
baseline and follow-up) in 8/65 MBLlo individuals (data not
shown), making it impossible to validate solid conclusions
regarding the potential association with the risk for pro-
gression into MBLhi and CLL. To the best of our knowl-
edge, the frequency and impact on disease progression of
recurrent mutations (i.e., NOTCH1, SF3B1, MYD88, etc.)
found in CLL, and also in MBLhi, to a lesser extent, has not
been elucidated for MBLlo.34–36  Therefore, analysis of these
CLL-related mutations in MBLlo cases might further con-
tribute to an improvement in better delineating intrinsic
tumor cell factors associated to disease progression.   
In addition, the environment in which CLL-like MBLlo
clones develop might be influenced by chronic immune
responses against e.g., host viruses, that might play a crit-
ical role in the expansion of clonal B cells, as recently sug-
gested.37 In line with this hypothesis, herein we also show
that the expansion of CLL-like MBLlo clones after seven
years of follow-up (vs. baseline) is accompanied by a sig-
nificant increase of all T-cell (but CD4+CD8+cytotoxic T-
cells) and NK-cell populations in PB.
Controversial results have been reported regarding PB T-
cell numbers in MBLlo. Hence, while te Raa et al. found
normal CD4+ and CD8+ T-cell counts in PB of MBLhi,38
other studies have demonstrated that around half of the
MBLlo individuals show ≥1 clonal/oligoclonal CD4+CD8+
T-cell population, with an overall increased frequency of
clonal T-cell populations vs. age-matched individuals from
the general population.10,39 However, the presence of clonal
(CD4+CD8+ and other) T-cell expansions has also been
described as a common event in older individuals, and has
been associated with the ageing of the immune system.39
In this respect, we demonstrate herein that changes in the
number of circulating PB T-cell and NK-cell populations
among our CLL-like MBLlo subjects were not age-related,
via a parallel analysis of a large group of 250 age- and sex-
matched non-MBL controls (Online Supplementary Table
S5). From a pathophysiological point of view, the increase
in most PB T- and NK-cell populations could be associated
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Table 5. Variables studied in the Cox regression multivariate analysis
showing an independent impact (P<0.1) on OS for the whole MBLlo
plus non-MBL cohort.
Variables HR (95%CI) P
Whole cohort
Cardiovascular disease 2.65 (1.30 - 5.41) 0.007
Age (<65y vs. ≥65y) 5.08 (1.48 - 17.49) 0.01
Solid tumor 2.86 (1.26 - 6.46) 0.01
MBLlo clones 2.14 (0.97 - 4.72) 0.06
CI: confidence interval; HR: hazard ratio; MBLlo: low-count monoclonal B-cell lympho-
cytosis; N: number; OS: overall survival; PB: peripheral blood. The complete list of vari-
ables analyzed in the Cox regression model is provided in Online Supplementary
Table S6.
del(13q14)(RB1)
Baseline 0/2 (0%) 3/13 (23%); 14±3.2% NS
follow-up NA 1/7 (14%); 47% NA
Trisomy 12
Baseline 0/3 (0%) 1/11 (9%); 59% NS
follow-up 0/9(0%) 1/40 (3%); 70% NS
del(11q)(ATM)
Baseline 0/2 (0%) 0/6 (0%) NS
follow-up 0/9 (0%) 0/39 (0%) NS
del(17p)(TP53)
Baseline 0/2 (0%) 0/5 (0%) NS
follow-up 0/9 (0%) 1/39 (3%); 10% NS
t(14q32)
Baseline NA NA NA
follow-up 0/3 (0%) 5/20 (25%); 31±33% NS
#2/56 individuals carried a clonal MBLlo CLL-like population along with at least one MBLlo non CLL-like clone. Results expressed as median (range) or as *number of cases (per-
centage). Cytogenetic alterations are expressed as percentage of cases and mean percentage of cells affected ± SD. P-values shown in the right column refer to comparisons
between MBLlo subjects who showed decreased/stable vs. increase clone sizes, while P-values shown in rows represent differences among subjects within each group at baseline
and after seven years of follow-up. CLL: chronic lymphocytic leukemia; MBLlo: low-count monoclonal B-cell lymphocytosis; N.: number; NA: not applicable; NK: natural killer; NS:
not statistically significantly different (P>0.05).
with either a potentially protective or activating effect of
these cellular components of the immune system
(microenvironment) on the expanded clonal B-cells.40,41
Therefore, on one hand, increased numbers of (functional-
ly impaired) T cells have been described in CLL38,42,43 while
on the other hand, we have recently shown increased
titers of plasma antibodies against CMV and EBV in MBLhi
and CLL patients vs. MBLlo and non-MBL controls, despite
their antibody (immune)deficient state.37 Taken together,
these latter findings might further support the existence of
additional signals coming from immune cells other than
clonal B cells, that could already contribute to the expan-
sion of (cyto)genetically altered CLL-like clones at the ear-
liest stages of disease, by promoting activation, prolifera-
tion and/or survival of specific B-cell clones.
A major goal of our study was to investigate the medi-
um-term rate of progression of MBLlo to MBLhi and (poten-
tially also) CLL. Overall, only one subject evolved from
MBLlo to MBLhi, and none transformed to CLL, which
would translate into a progression rate from MBLlo to
MBLhi of 1.8% after seven years of follow-up. Despite the
fact that the rate of progression of MBLlo to MBLhi and CLL
appears to be extremely low, one of the most astonishing
findings of our follow-up study was the significantly high-
er frequency of deaths among MBLlo subjects, associated
with a significant adverse impact on OS vs. both non-MBL
controls, particularly among females, and the general pop-
ulation (of similar age and sex distribution) living in the
same region in Spain. However, comparisons with the
general population must be considered with care, since
the conditions of this population might differ from that of
non-MBL individuals recruited at the Primary Health
Services. Multivariate analysis showed a borderline signif-
icant association between the presence of MBLlo clones and
a shorter survival. Despite this, the specific mechanisms
responsible for the higher frequency of infections and
deaths observed, particularly among women, are
unknown, and further studies are required to validate and
clarify these results. In this regard, controversial results
have been reported on MBLhi subjects in the literature.
Thus, while Shanafelt et al. showed no differences in OS
of MBLhi vs. the general population,33 Shim et al. pointed
out a higher frequency of deaths in their MBLlo cohort
(4/11; 36%), albeit no statistically significant differences
were found vs. non-MBL controls in the latter study, prob-
ably due to the small sample size.22 In addition, Fazi et al.
also reported that 16/137 (12%) CLL-like MBLlo subjects
died before re-evaluation after a median time of three
years, which is a high proportion of their whole cohort.10
However, in the aforementioned report no information
about the age of the deceased subjects is provided, and
therefore, if it is the case they were older (than those sub-
jects remaining alive) such high mortality rates might have
been expected. Even more strikingly is the overrepresenta-
tion of infections as causes of death in MBLlo compared to
that of our non-MBL cohort. Impaired immune responses
and higher frequencies of infection have been recurrently
reported in both MBLhi and CLL,44–47 but so far very little
information exists in MBLlo, and such an association
deserves further investigations. Several groups pointed out
that the frequency of clonal hematopoiesis dramatically
increases with age in the general population, especially
among the elderly, in a similar way to the increased fre-
quency of MBLlo, reflecting a clear relationship between
clonal hematopoiesis and a higher risk of death.48,49
Whether or not both phenomena are related to MBLlo
deserves future investigations. 
In summary, we show herein that although MBLlo is a
persistent and dynamic condition with a progressive
acquisition of cytogenetic alterations, usually associated
with an increased clone size and higher T- and NK-cell
numbers in PB over time, progression of MBLlo to MBLhi
and CLL is extremely rare in the medium-term. Despite
this, the MBLlo subjects analyzed herein, particularly
women, showed a shortened OS associated with an
increased risk of death, particularly due to infections, fur-
ther supporting the notion that MBLlo could be a marker of
an impaired immune system, indirectly associated with a
poorer outcome. Additional studies are necessary to con-
firm these findings and shed light onto the specific
immune defects and microenvironmental factors involved
in MBLlo.
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